Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia

NCT04331665 · clinicaltrials.gov ↗
NA
Phase
TERMINATED
Status
3
Enrollment
OTHER
Sponsor class

Stopped A Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint. With this news, recruitment was stopped for this study.

Conditions

Interventions

Sponsor

University Health Network, Toronto